Barinthus Biotherapeutics (BRNS) is currently trading at $1.09, down 4.58% recently, reflecting market concerns over its cost-cutting measures, including layoffs and site closures, despite extending its cash runway to 2027. Analysts maintain a bullish view with a "Strong Buy" rating and a revised price target of $3, citing potential upside from its strategic focus on promising drug candidates like VTP-300 and VTP-1000. Positive interim Phase 2 trial results for VTP-300 further support optimism for long-term growth.